Entera Bio (ENTX) Equity Average (2018 - 2026)

Entera Bio has disclosed Equity Average across 8 years of filings, most recently posting $11.9 million for Q1 2026.

• Quarterly Equity Average fell 13.37% year-over-year to $11.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.9 million (down 13.37% YoY) and the FY2025 annual result came in at $10.6 million, up 14.7% from the prior year.
• Equity Average retreated to $11.9 million in Q1 2026, from $14.2 million in the prior quarter.
• Over five years, Equity Average peaked at $21.2 million in Q1 2022 and troughed at $7.2 million in Q3 2023.
• A 5-year average of $12.4 million and a median of $11.9 million in 2026 frame the typical range for Equity Average.
• Annual changes were most pronounced in 2023 — Equity Average tumbled 54.19% — and 2025, when it soared 116.83%.
• Tracing ENTX's Equity Average over 5 years: stood at $13.0 million in 2022, then tumbled by 36.23% to $8.3 million in 2023, then dropped by 12.57% to $7.3 million in 2024, then soared by 94.98% to $14.2 million in 2025, then slipped by 16.05% to $11.9 million in 2026.
• Business Quant data shows ENTX's Equity Average at $11.9 million in Q1 2026, $14.2 million in Q4 2025, and $16.2 million in Q3 2025.